AUTHOR INDEX

Volume 34, 1996

Abe, M., 57, 513, 859, 1105
Adams, G.E., 79
Adler, D., 571
Aghdam, H., 481
Ahmed, M.M., 161
Ai, D., 1105
Akaboshi, M., 1081
Akagi, Y., 333
Akuta, K., 1081
Alden, M.E., 403
Allalunis-Turner, M.J., 367
Allgood, J.W., 381
Altemus, R., 481
Althof, V.G.M., 697, 709
Amin, P.P., 663
Amos, W.R., 289
Andrews, J.C., 155
Anscher, M.S., 745
Arastu, H., 1097
Ardiet, J.-M., 775
Arimura, H., 1105
Asbell, S., 1097
Aussems, P., 297
Awwad, S., 323
Ayyangar, K.M., 1147
Ayzac, L., 775

Bahary, J.-P., 647
Bakker, A.J., 887
Bakker, P.J.M., 887
Baral, E., 41
Barbet, N., 775
Barker, F.G., II, 803
Barnes, M., 853
Barrett, R.J., 139
Bartelink, H., 953
Bates, J.H.T., 243
Bayle, P., 579
Beard, C.J., 451
Belkacémi, Y., 71
Belzer, F.O., 1055
Benchimol, S., 341
Bentel, G.C., 793
Bentzen, S.M., 421
Bernier, J., 953
Best, L.A., 1125
Bier, J., 635
Bissett, R., 489
Bleier, A.R., 183
Blondon, J., 1019
Blosser, E.B., 411
Blosser, G.F., 411
Blosser, H.G., 411
Boellaard, R., 931
Bonin, S.R., 167
Borak, T.B., 125
Borgen, P., 565
Bosch, W.R., 683, 943
Bostwick, D.G., 33
Bova, F.J., 591, 785
Boyer, A.L., 555
Boyko, S., 489
Brail, L., 341
Brenner, D.J., 511, 905
Brewer, E.A., 543
Brickner, T.J., 13
Bristow, R.G., 341
Britten, R.A., 367
Brown, M., 793
Brown, S.L., 133
Brunin, F., 277
Buatti, J.M., 591, 785
Buffat, L., 1019
Burger, P., 793
Bussière, M., 451
Bussières, E., 21, 49
Butler, E.B., 183
Byrne, T., 793

Cairncross, J.G., 793
Calvert, A.S., 357
Camel, H.M., 27
Capizzi, R.L., 1073
Carol, M., 183
Case, B.C., 1087
Cassapi, L., 149
Cassisi, N.J., 289
Castro-Vita, H., 3
Cenni, J.-L., 775
Cha, C., 155
Chalas, E., 139
Chang, E.Y., 617, 867
Chang, S.M., 803
Chao, C.K.S., 27
Chappell, R., 1055
Chatterjee, N., 1121
Cheang, M., 41
Chen, A., 911
Chen, G.T.Y., 205, 213
Chen, Y., 103
Cheng, A., 943
Childress, C.H., 555
Chou, R.H., 843
Christie, D.R.H., 1045
Chu, J.C.H., 727
Chung, S., 341
Cionini, L., 953
Cline, J.M., 1087
Coia, L.R., 823
Colacchio, T.A., 125
Coleman, C.N., 451
Coppey, J., 1061
Coquard, R., 775
Corn, B.W., 167
Coss, R.A., 403
Costello, P., 451
Cottier, B., 149
Cowan, M.J., 843
Creutzberg, C.L., 697
Crittenden, M.R., 843
Crownover, R.L., 911
Cuddy, P.G., 543
Cuillière, J.-C., 21
Cumberlin, R., 227
Cummings, B.J., 445
Cundiff, J., 173
Curran, B.H., 189
Curran, W., 1097
Curran, W.J., Jr., 823

Dale, J., 1125
D'Alessandro, A.M., 1055
Damilakis, J., 315
D'Angio, G.J., 899
Daoud, K., 1125
Dargent, D., 21
Davey, P., 647
Davis, M.A., 617
Davis, R.L., 803
de Geus, B.W.J., 1037
de Hoog, M., 697
Delannes, M., 21, 49
Delrowe, J., 1097
Del Rowe, J., 647
DeLuca, A.M., 853
Deniaud, E., 1019
Denman, D.L., 1087
De Ranieri, J., 21
Deschavanne, P.J., 251
Desjardins, L., 277
Deutschmann, H., 1133
Dewhirst, M.W., 1087
Dieckmann, K., 635
Diep, K., 623
Dinapoli, R., 647
Dodge, R.K., 1087
Doty, J., 103
Dropcho, E., 793
Drukker, K., 873
Drzymala, R.E., 469
Dubois, J.-B., 21, 49
Duclos, M., 655
Dunn, P.A., 579
Dunscombe, P., 489

Earle, J.D., 33
Eisenberg, B.L., 1009
Eisenberg, H., 663
El-Badawy, S., 85
El-Mahdi, A.M., 809
Emami, B., 1097
Engler, M.J., 189
Ensminger, W.D., 155, 617
Erlichman, C., 445
Essers, M., 931
Evans, A.J., 367
Evans, K., 579
Evans, S.M., 1087

Fang, Y., 309
Fein, D.A., 289, 733, 823, 1009
Felix, R., 635
Fernandes, D.J., 1073
Ferrigni, R.G., 535
Fertil, B., 251
Fischer, B., 793
Fisher, B., 647
Flam, M., 65
Flynn, D.F., 221
Forman, J.D., 411, 655, 691
Fowble, B.L., 733, 1009
Fraser, W.D., 149
Friedman, A., 793
Friedman, W.A., 591, 785
Frost, P.J., 817
Fu, K., 1097
Fu, K.K., 911
Fuji, H., 389
Fujimori, K., 1029
Fujita, M., 333
Fukuda, Y., 459

Gallagher, M.J., 965
Gansow, O.A., 609
Ganzevles, P.G.J., 1037
Garcia, D., 995
Gaspar, L., 793
Gastorf, R., 227
Gelman, R., 451
Gérard, J.-P., 21, 49, 775
Gerber, R.L., 943
Gery, B., 1061
Giatromanolaki, A., 315
Gilhuijs, K.G.A., 873
Gillette, E.L., 125
Gillette, S.M., 125
Gilly, F.-N., 49
Gladstone, D., 451
Goldwein, J.W., 899
Gonzalèz, D.G., 887, 953
Gorin, N.-C., 71
Grado, G.L., 535
Graham, M.V., 469, 943
Grant, W.H., III, 183
Griffin, T.W., 111
Grigsby, P., 1097
Grigsby, P.W., 3, 27
Groebe, K., 395
Grzeszczuk, R., 205
Guillard, Y., 21
Guillemin, F., 21
Gunderson, L.L., 677, 741
Gutin, P.H., 803

Haberer, T., 599
Hahn, P., 41

Hahn, T.M., 867
Hait, W., 793
Hall, E.J., 79, 511, 905
Halperin, E.C., 793
Halverson, K., 995
Halyard, M.Y., 535
Hamers, H., 953
Hamilton, R., 213
Hanks, G.E., 13, 167, 235, 549, 733
Hanlon, A.L., 13, 549, 823, 1009
Hanna, M., 139
Haraf, D.J., 205
Harisiadis, L., 481
Harrington, K.J., 579
Harrison, J., 213
Harrison, M., 579
Harter, K.W., 475
Hartsell, W.F., 727
Hartz, W.H., 167
Hauer-Jensen, M., 381
Hayakawa, Y., 389
Haye, C., 277
He, T., 691
Hei, T.K., 79
Heilmann, J., 599
Heimann, R., 205
Helvie, M., 571
Hermans, J., 297
Herndon, J., 793
Hertel, L.W., 867
Herzog, T., 27
Hill, R.P., 341, 623
Hind, C.R.K., 149
Hinerman, R.W., 289
Hiraoka, M., 1105
Hirokawa, Y., 333
Hirst, V.K., 357
Hlouverakis, G., 315
Hoekstra, C.J.M., 709
Hoffman, J.P., 1009
Hogan, W.M., 167
Holland, J., 911
Homesley, H.D., 139
Horiot, J.-C., 953
Horton, J., 227
Hosoba, M., 1105
Hsue, V., 445
Huang, D.T., 1141
Huang, Y., 905
Huilgol, N.G., 1121
Huizenga, H., 697

Imamura, M., 57
Imperato, J., 793
Inoue, T., 235
Itai, Y., 389

Jack, C.I.A., 149
Jackson, M.J., 149
Jahnke, V., 635
Jain, N.L., 469
Jang, A., 341
Janjan, N.A., 923
Jaros, E., 323
Jeremic, B., 303
Johansson, K.-A., 953
John, M., 65
Johns, H., 357
Johnson, G.W., 905
Johnson, J., 899
Johnstone, P.A.S., 853

Kahn, M.G., 469
Kamada, T., 767
Kamphorst, W., 895
Kania, A.A., 183
Karim, A.B.M.F., 895
Kashimoto, K., 333
Kashiwado, K., 333
Kazusa, C., 1105
Kelly, C.A., 727
Khandekar, J., 793
Khil, M.S., 133, 375
Kijewski, P., 451
Killion, L.T., 543
Kim, J.H., 133, 375
Kim, S.-H., 133
Kim, S.H., 375
Kinashi, Y., 1081
Kinsella, T.J., 853, 1055
Kiriu, H., 333
Klein, E.E., 117, 1153
Kline, R., 647
Knechtle, S.J., 1055
Kobayashi, T., 1081
Koch, C.J., 93
Kodner, I.J., 1153
Kogelnik, H.D., 1133
Koh, W.-J., 111
Kokubo, M., 1105
Kolm, P., 809
Komaki, R., 173
Kopplin, S., 555
Korb, L.J., 917, 1147
Korbas, D., 71
Kosma, L., 315
Kostyra, J., 41
Koukourakis, M., 315
Kraft, G., 599
Kralendonk, J.H., 895
Kramer, J.H., 843
Kranzinger, M., 1133
Krieg, R., 911
Krishna, K.V., 1147
Krithivas, V., 197
Krol, A.D.G., 297
Kurita, Y., 1029
Kuroiwa, T., 663
Kurth, K.-H., 887
Kuske, R.R., 995
Kuten, A., 1125

Labat, J.-P., 429
Laderoute, K.R., 79
Lambert, H.E., 579
Lamborn, K.R., 803
Lanciano, R.M., 167
Langberg, C.W., 381
Langmuir, V.K., 79
Lanson, H., 931
Laperriere, N.J., 817
Laporte, J.-P., 71
Larson, D.A., 803, 1113
Larson, T.R., 535
LaRue, S.M., 125
Laskin, W.B., 853
Laugier, A., 71, 1019
Laurent, M., 277
Lawrence, T.S., 155, 617, 867
Leahy, T.J., 227
Leblond, V., 71
Lee, J., 1087
Lee, W.R., 289, 549, 823
Leer, J.W.H., 297
Lefranc, J.-P., 1019
Legorreta, R.L., 1087
Lentz, S.L., 139
Leslie, S., 809
Leszczynski, K., 489
Levendag, P.C., 497, 697
Lewis, A.M., 103
Lichter, A., 571
Ling, C.C., 13, 1113
Ling, S.M., 221
Little, J.B., 1061
Liu, F.-F., 623
Liu, S.-X., 79
Lo, Y.-C., 1113
Lockett, M.A., 3, 995
Loeffler, J., 647
Löffel, J., 635
Löffler, E., 1153
Loose, S., 489
Lord, E.M., 93
Low, D.A., 117, 683
Lozac'h, P., 429
Lucas, B., 429
Lunec, J., 323
Lynn, J., 579

Maag, D.K., 117
Macdonald, D.R., 793
Mackillop, W.J., 243
MacLeod, M., 445
Madsen, E.H., 421
Mahé, M.-A., 21, 49
Makino, S., 459
Malhaire, J.-P., 429
Malissard, L., 21
Mammar, H., 1019
Manabe, T., 57
Marcus, R.B., Jr., 785
Marks, L., 647
Marks, L.B., 1165
Martel, P., 21
Martenson, J.A., 677
Masunaga, S.-I., 1081
Math, M., 41
Matsumoto, S., 833
Matthay, K.K., 843
Maughan, R.L., 411
McCormick, B., 565
McDermott, M.W., 803
McGee, K.P., 733
Medvedovsky, C., 905
Meffan, P.M., 1045
Mehta, A.R., 1121
Meigooni, A.S., 1153
Mendenhall, W.M., 289, 591, 785
Mendonca, H.L., 79
Menzel, C., 1133
Merajver, S., 571
Merchant, T.E., 565
Merz, F., 1133
Mesina, C.F., 691
Michalski, J.M., 683, 943
Mijnheer, B., 931
Miller, R.W., 905
Million, R.R., 289, 507
Milosevic, M.F., 817
Milstein, D., 1125
Min, K.-Y., 459
Minsky, B.D., 961
Mitsumori, M., 1105
Miyao, H., 1029
Miyauchi, K., 439
Mizowaki, T., 1105
Mohiuddin, M., 161, 963
Montesano, A., 1097
Moore, M., 445
Morikawa, M., 663
Morisawa, H., 1105
Moros, E., 1097
Morowitz, R., 793
Morum, P.E., 1045
Moshang, T., 899
Mueller-Klieser, W., 395
Mullen, J.R., 983
Murata, R., 859, 1105
Mutch, D.G., 27
Myerson, R.J., 683, 1153

Nagata, Y., 1105
Nakata, M., 1105
Nakayama, Y., 459
Naylor, M.A., 79
Nielsen, O.G., 421
Nielsen, O.S., 85
Niroomand-Rad, A., 475
Nishidai, T., 1105
Nishimura, Y., 57
Nishiyama, K., 439
Nojima, T., 767
Noordijk, E.M., 297
Novicki, D.E., 535
Noyes, W.R., 1055
Numaguchi, Y., 663
Nussbaum, G.H., 1153

Ochran, T.G., 173
Oesterling, J.E., 33
Ohara, K., 389
Ohsawa, N., 459
Ohshio, G., 57
Ohtani, K., 333
Okagawa, K., 439
Okajima, K., 1105
Okushiba, S.-I., 767
Oleson, J.R., 1087
Ono, K., 1081
Orton, C., 655
Ostrom, L.T., 227
O'Sullivan, B., 243
Overgaard, J., 85, 421
Overgaard, M., 421
Owen, J.B., 13, 235

Oya, N., 859
Ozsahin, M., 71

Packer, R.J., 899
Page, R.L., 1087
Paleologos, N., 793
Palma, N., 65
Pardo, F.S., 103
Parsons, J.T., 289
Pawlicki, T., 917
Peacock, J., 341
Pearcey, R.G., 367
Pelizzari, C.A., 205
Pène, F., 71
Perez, C.A., 3, 27, 995, 1097
Peterson, L.M., 111
Phil, D., 511
Piepmeier, J., 793
Pierce, L., 571
Pinto, J.T., 375
Pirsch, J.D., 1055
Pisansky, T.M., 33
Plunkett, M., 451
Pollack, A., 555, 983
Porter, A.T., 655
Postma, A.J., 887
Powers, B.E., 125
Powers, W.E., 411
Prados, M.D., 803
Prescott, D.M., 1087
Purdy, J.A., 117, 469

Radcliffe, J., 899
Ragan, D.P., 691
Rahim, H.B.K., 1133
Randall, M.E., 139
Randers-Pehrson, G., 905
Rathbun, P., 227
Razavi, R., 475
Regine, W.F., 963
Richaud, P., 21, 49
Ridge, J.A., 823
Riess, H., 635
Rietbroek, R.C., 887
Rigamonti, D., 663
Rio, B., 71
Roach, M., III, 749, 911
Robertson, J.M., 155
Robinson, E., 1125
Rocher, F.-P., 775
Rodriguez, R., 1055
Roelss, R., 41
Rojas, A., 357
Romestaing, P., 775
Rooker, G.M., 543
Rorke, L.B., 899
Rosen, I.I., 555, 923
Rosenfeld, S., 793
Rosner, G.L., 1087
Rothman, M.I., 663
Rouanet, P., 49
Roussel, A., 21, 49
Rubin, P., 1097
Ruble, G., 609
Ryan, M.J., 205
Ryu, S., 133

Safwat, A., 85
Saidan, Z., 579
Saito, M., 1029
Saitou, H., 767
Salter, M., 793
Samulski, T.V., 1087
Sasai, K., 57, 859
Sato, S., 235
Saute, M., 1125
Saw, C.B., 917, 1147
Sawyer, T.E., 585
Scheller, S., 635
Schild, S.E., 535, 585, 677
Schilthuis, M.S., 887
Schlienger, M., 71, 1019
Schlienger, P., 277
Schmitt, T., 21
Schold, S.C., Jr., 793
Scholz, M., 599
Schulsinger, A., 717
Schultheiss, T.E., 549, 733
Schultz, C., 647
Scott, C., 647, 1097
Scott, R.J., 125
Sedlmayer, F., 1133
Shaeffer, J., 809
Shaffer, K., 451
Shamsa, F., 655
Shank, B., 753
Shaw, E., 647
Shaw, E.G., 585
Shewach, D.S., 867
Shibamoto, Y., 57, 303, 513, 859
Shibata, T., 859
Shibuya, H., 833
Shimizu, A., 459
Shin, K., 647
Sigurdson, E.R., 1009
Simard, J.M., 663
Simon, H., 429
Simpson, W.J., 817
Sindelar, W.F., 853
Skarlatos, J., 315
Skoczylas, J.Z., 421
Skuse, G.R., 509
Skwarchuk, M.W., 173
Slivjak, A., 549
Slotman, B.J., 895
Smith, A.R., 13
Smith, N.N., 403
Sneed, P.K., 803
Sollinger, H.W., 1055
Somes, J., 323
Song, M., 309
Song, P.Y., 213
Souhami, L., 647
Souquet, J.-C., 775
Spelbring, D., 213
Spevack, L., 543
Spirtos, N.M., 139
Spry, N.A., 1045
Squire, R.A., 609
Stahl, H., 635
Starkschall, G., 555, 923
Stelzer, K.J., 111
Sternick, E.S., 189
Stetson, P.L., 617
Stewart, J.S.W., 579
Strand, M., 609
Stringer, S.P., 289
Stukel, T.A., 125
Su, M., 103
Sugahara, K., 1105
Suman, V.J., 33
Sung, C.-C., 381
Suntharalingam, N., 717
Sutherland, R.M., 79
Sutton, L.N., 899
Suzuki, S., 833
Swanson, S.K., 535
Swift, P., 1097
Swift, P.S., 843

Takagaki, M., 1081
Takagi, T., 859
Takahashi, M., 57
Takamura, A., 767
Takeda, M., 833
Tanaka, E., 439
Tannock, I.F., 623
Targovnik, H.S., 183
Tarui, Y., 439
Tatsuzaki, H., 389
Taucher-Scholz, G., 599
Taylor, M.E., 995
Teague, S., 1153
te Loo, H.-J., 709
Teshima, T., 235
Theele, D.P., 591
Thobejane, S., 475
Thrall, D.E., 1087
Tinger, A., 683, 943
Topart, P., 429
Touboul, E., 71, 1019
Touw, A., 873
Travis, E.L., 173
Tsai, J.-S., 189
Tsunemoto, H., 235
Twijnstra, A., 1037

Uematsu, T., 1029
Umfleet, W.E., 117

Vaida, F., 213
Valicenti, R.K., 683, 943
van Alphen, H.A.M., 895
van den Aardweg, G.J.M.J., 497
van den Bogaert, W., 953
van de Ven, P.J.H., 873
van Herk, M., 873, 931
van Oosterhout, A.G.M., 1037
van Vonderen, R.G.M.W., 1037
Vazquez, M.E., 905
Veenhof, C.H.N., 887
Venkatasubbarao, K., 161
Vick, N., 793
Vijayakumar, S., 205, 213
Vilcoq, J.R., 277
Visser, A.G., 497, 697
Volant, A., 429
Vörding, P.J.Z.V.S., 887
Vujaskovic, Z., 125

Wachsberger, P.R., 403
Wada, T., 333
Wang, G., 309
Wang, X.-Y., 727
Wara, D.W., 843
Wara, W.M., 843
Washington, M., 213
Waterman, F.M., 717
Weiss, J., 125
Wessels, B., 481
West, J.C., Jr., 543
Wharam, M., 647
Wheeler, K.T., 1073
White, P.J., 1141
Wijnmaalen, A., 697
Williamson, J.F., 1153
Willoughby, T.R., 923
Wilmink, J.T., 1037
Wilson, C.B., 803
Withers, H.R., 243
Wong, C.S., 445, 817
Wong, G.B., 843
Wong, J., 943
Wong, W.W., 535, 585
Woo, S.W., 183
Woods, M.L., 93
Worgul, B.V., 905
Wu, A., 917
Wu, B., 905
Wu, C., 609
Wust, P., 635
Wyman, B., 213

Xu, H., 309

Yahalom, J., 565
Yamamoto, M., 1105
Yamashita, T., 521
Yang, J.-L., 1073
Yannakakis, D., 315
Yokoyama, A., 1029
Yorke, E., 481
Young, B.K., 911
Yu, Y., 717
Yudelev, M., 411

Zagars, G.K., 555, 983
Zen-Al-Deen, I., 1125
Zhu, A., 809
Zhu, Y., 1153
Zincke, H., 33
Zoarski, G.H., 663
Zwicker, R.D., 1141

SUBJECT INDEX

Volume 34, 1996

A

Abdominal radiotheapy, 139
Acceleration, 357
Accelerator reticle system, 197
Accident investigation, 227
Activated T-cells, 459
Acute toxicity, 555
AK-2123, 1121
Alpha-emitter, 609
Anal cancer, 65
Antigens, 543
Aquaplast, 213
ARCON, 357
Arteriovenous malformation, 663
Artificial intelligence, 923
Artificial neural network, 923
Association of Residents in Radiation Oncology (ARRO), 221
Astrocytic tumors, 809
Astrocytoma, 785
^{198}Au grain, 833

B

Backscatter, 475
BAL, 459
BCNU, 793
BG-1 human ovarian carcinoma cells, 1073
Biological clearance, 389
Bioreductive drugs, 79
Bladder cancer, 887
Bone-marrow transplantation, 71
Bone marrow transplantation, 85
Boost field, 1009
Boost planning, 1133
BPA, 1081
Brachytherapy, 173, 497, 717, 833, 905, 917, 1097, 1133
Brachytherapy boost, 995
Brain irradiation, 585
Brain metastasis, 585
Brain neoplasms, 785, 793
Brain tumors, 647
BrdUrd, 1073
Breast, 733
Breast cancer, 565, 571, 1133
Breast-conservation surgery, 1009
Breast-conservation therapy, 995
Breast-conserving therapy, 565
Breast electron boost, 579
Breast implant, 1133
Breast irradiation, 727
Breast recurrence, 1009
Bromodeoxyuridine, 617, 803
Bronchial arterial infusion, 309
Bronchogenic cancer, 309
BSH, 1081

C

CA 19-9, 57
Canine, 853
Canine sarcomas, 1087
Carbogen, 357
Carcinogenesis, 853
Carcinoma of the uterine cervix, 21
Carcinoma of uterine cervix, 3
Carmustine, 793
Catalytic iron, 149
Cervical cancer, 167
Cervical carcinoma, 887
Cervical lymph node metastases, 635
Cervix, 367
Chemotherapy, 65, 309, 793, 899, 1037
CHO-K1 cells, 599
Circulating minimal malignant clone (CMMC), 161
Cisplatin, 367, 887
c-Ki-ras, 161
Clinical radiobiology, 421
Clinical trials, 953
CNS neoplasms, 793
Cognitive impairment, 1037
Combined modality therapy, 139, 1019
Combined modality treatment, 65
Complications, 277
Computer-assisted radiotherapy, 785
Concomitant boost, 381
Conformal radiotherapy, 555
Conformal therapy, 183, 411, 451, 709, 1105
Conservation surgery, 983
Contact x-ray therapy, 1153
Contralateral breast dose, 727
Cooperative groups, 953
Craniospinal irradiation, 899
CT, 205
CT simulation, 691
Cyclophosphamide, 85
Cytoreductive therapy, 1045
Cytoskeleton, 403

D

Decision theory, 469
Deoxynucleotides, 867
Digitally reconstructed radiograph, 873
Discontinuous accelerated hyperfractionated radiation, 1121
DNA DSB-induction, 599
Dose escalation, 655
Dose inhomogeneity, 1141
Dose perturbation, 475
Dose prescription, 173
Dose rate, 85
Dosimetry, 173, 197, 481, 555, 917, 931, 1147, 1153

E

E1a, 103
Edge extraction, 489
EF5, 93
Effect-depth distribution, 599
Electron beam boost, 995
Electronic portal imaging devices, 117
Electronic portal imaging, 683
Electrons, 277
EMT6 tumors, 93
Endobronchial, 173
Endocavitary irradiation, 775
Endocavitary radiotherapy, 677
Endometrial carcinoma, 27
EPID, 733
Epidermal growth factor receptor, 809
Erythroleukemia, 609
Esophagus cancer, 429
Ethacrynic acid, 375
Exogenous lactate, 395
Expandable metallic biliary endoprosthesis, 767
External beam radiation, 41
External beam therapy, 1147
External iliac lymph nodes, 167
Extrahepatic bile duct cancer, 767
Eyelids, 277

F

Facility survey, 235
Fibroblastic matrix, 1061
Field matching, 183
Floor of mouth, 833
Flow cytometric analysis, 93
5-Fluorouracil, 445
Flutamide, 911
Folinic acid, 445
Fractionation, 71, 357, 1113

G

Gamma knife, 663
Gantry, 189
Gemcitabine, 867
Genomic instability, 103
Geographical miss, 579
Glioblastoma multiforme, 785, 803, 895
Gliomas, 793
Goserelin, 911
Grade, 33
Gynecological cancer, 13

H

HDR, 173, 1153
Head and neck, 323
Head and neck cancer, 475

Head and neck cancers, 1121
Heavy ion therapy beams, 599
Hepatic artery chemotherapy, 155
Hepatic toxicity, 911
High-energy x-ray therapy, 1141
Hormonal therapy, 535
H-ras, 103, 341
Human carcinoma cells, 375
Human cell lines, 367
Human cells, 251
Human colon carcinoma spheroids, 395
Human factors, 227
Human papillomavirus, 341
Human prostate carcinoma, 133
Human tumor cells, 1061
Human tumor xenografts, 617
Hydroxylapatite coating, 475
Hyperfractionated radiotherapy, 309
Hyperfractionation, 139, 303, 655
Hyperthermia, 403, 623
Hyperthermia induced, 887
Hypofractionation, 895
Hypoxic cell sensitizer, 1121
Hypoxic cytotoxicity, 79
Hypoxic fraction, 859

I

ICAM-1, 459
Image registration, 489
Immobilization, 213
Immunohistochemistry, 809
Inhomogeneity correction, 481
Inoperable, 27
Instantaneous dose rate, 71
Intensity modulation, 183
Interfraction interval, 303
Interstitial hyperthermia, 1097
Interstitial implant, 1133
Interstitial pneumonitis, 71
Interstitial radiotherapy, 1097
Intracellular pH, 623
Intracellular pH measurements with heating, 623
Intracellular pH regulators, 623
Intraluminal, 767
Intraluminal brachytherapy, 1029
Intraoperative hyperthermia, 125
Intraoperative radiation therapy, 21, 49
Intraoperative radiotherapy, 57, 853
Intraopertive irradiation, 125
Intratreatment and intertreatment displacements, 683
Intrinsic radiation sensitivity, 103
Intrinsic radiosensitivity, 251
In vitro, 251
In vivo dosimetry, 931
^{125}Iodine, 717
^{192}Ir, 767
^{192}Iridium, 173
Irradiation, 439
Isocenter, 189

L

Laryngeal neoplasms, 823
Late effects, 905
Late toxicity, 65
^{212}Lead, 609
Leuprolide, 911
Linear accelerator, 189
Lipid peroxidation, 149
Liver damage, 911
Liver metastases, 155
Local hyperthermia, 635, 1087
Localized prostatic cancer, 1045
Locally advanced, 571
Locally advanced noninflammatory breast cancer, 1019
Locally advanced prostate cancer, 655
Local recurrence, 49, 155
Long-term follow-up, 41
Low dose rate, 1029, 497
Lung, 85
Lung cancer, 297, 459, 469, 481
Lung corrections, 1141
Lymphangiogram, 167
Lymphatic metastasis/di [diagnosis], 33
Lymph node, 33
Lymph node excision, 543

M

Malignant fibrous histiocytoma, 983
Malignant meningioma, 817
Mammography, 571
Matchline, 183
Mathematical model, 395
Mean inactivation dose, 251
Medulloblastoma, 899
6-Mercaptopurine, 793
Metastases, 647
Metastasis, 341, 357
Metastatic brain tumors, 389
Metastatic potential, 103
Methylprednisolone, 591
Micronucleus, 1081
Mild hyperthermia, 133
Misadministrations, 227
Mitomycin C, 793
Modulation of DNA precursor pools, 1073
Monoclonal antibody, 609
Monte Carlo, 1153
Morbidity of therapy, 3
MR angiography, 663
MR imaging, 663
Multicellular tumor spheroids, 395
Multirod collimator, 411
Myxoid malignant fibrous histiocytoma, 983

N

Na^+/H^+ antiport, 623
Necrosis formation, 395
Neoadjuvant, 1125
Neoplasm, 323
Neoplasms, 277
Network, 1105
Neurocognitive sequelae, 899
Neuropsychologic testing, 899
Neurotoxicity, 1037
Neutron therapy, 411
Nicotinamide, 357
2-Nitroimidazole, 93
Nonequilibrium, 1141
Nonsmall cell lung cancer, 303, 315
Normalized total dose, 315
Normal-tissue effects, 421
NSCLC, 1125
Nucleoside analogs, 617

O

Older-aged women, 565
Oncogenicity, 79
On-line radiation therapy imaging, 117
Optimization, 923
Oral cavity, 475
Orchidectomy, 1045
Oropharyngeal carcinoma, 289
Osteoradionecrosis, 333
Out-of-plane rotations, 873
Ovarian cancer, 139
Overall time, 357
Overall treatment time, 315

P

P53, 323
p53, 341
PACS, 1105
PALA, 1073
Pancreatic adenocarcinoma, 161
Pancreatic cancer, 57, 867
Pancreatic carcinoma, 445
Patient laser marking, 691
Patient motion, 213
Patient positioning, 697
Pediatric bone marrow transplantation, 843
Pelvic fields, 697
Pelvic radiotherapy, 167, 683
Pelvic recurrence, 21
Pentoxifylline, 111
Peripheral blood, 161
Peripheral nerve, 125
Photon beam, 1147
Plasminogen activator, 341
Pneumonitis, 111
Point mutation, 161
Polymerase chain reaction (PCR), 161
Portal imaging, 489, 697, 873, 931, 943
Possibility of breast conservation, 1019
Primitive neuroectodermal tumors, 899
Prognostic assay of survival, 403
Prognostic factor, 57
Prognostic factors, 803, 823, 895, 983
Prophylactic cranial irradiation, 1037
Prostate, 717
Prostate cancer, 33, 41, 213, 549, 911
Prostatectomy, 535
Prostate movement, 709
Prostate neoplasm, 451
Prostate-specific antigen/bl [blood], 33
Prostate specific antigen, 555
Prostatic neoplasma/pa [pathology], 33
Prostatic neoplasms, 543
PSA doubling time, 549
Psychometric testing, 1037
Pulsed dose rate, 497, 905

Q

Quality assurance, 173, 197, 931, 1133
Quality assurance in radiotherapy, 697
Quality control, 953
Quality management rule, 227
Quantitative assay, 421
Quiescent cells, 1081

R

Radiation, 367, 1009, 1087
Radiation-induced lung injury, 421
Radiation injuries, 381, 591
Radiation oncology, 853
Radiation oncology equipment, 235
Radiation oncology personnel, 235
Radiation Oncology training, 221
Radiation pneumonitis, 149, 459
Radiation protection, 591
Radiation response, 375
Radiation sensitizers, 617
Radiation therapy, 3, 27, 41, 155, 381, 451, 793, 917, 983, 995, 1055, 1147
Radiation therapy quality assurance, 117
Radiation treatment, 13
Radiochemotherapy, 429, 1125
Radiochromic film, 173, 1153
Radioimmunotherapy, 609
Radiopredictive assay, 1061
Radioresponsiveness, 389
Radiosensitivity, 341, 803, 1061
Radiosensitization, 1073
Radiosensitizers, 867
Radiosurgery, 591, 647, 663, 1113
Radiotherapy, 57, 65, 243, 277, 289, 297, 303, 315, 323, 357, 421, 445, 489, 497, 535, 709, 767, 817, 823, 833, 895, 899, 943, 953, 1029, 1045
Radiotherapy dosage, 785
Rat, 381
Rat embryo cells, 341
Rectal cancer, 49, 155, 677, 1153
Rectal carcinoma, 775
Recurrence-free survival, 809
Recurrent, 647
Reirradiation, 585
Remote afterloading system, 1153
Renal transplant rejection, 1055
Reoxygenation, 859
Resident survey, 221
Rodents, 357
Rodent tumors, 859
Roentogenographically occult endobronchial carcinoma, 1029
Rotational therapy, 183

S

SCCVII tumors, 1081
Sequelae, 277
Setup reproducibility, 733
Setup uncertainty, 1113
Single irradiation, 859
Small cell lung cancer, 1037
Small intestine, 381
Split-course, 309
Squamous cell carcinoma, 833
Stage, 33
Stage C prostate cancer, 535
Stage I, 297
Stereotactic, 647
Stereotactic radiosurgery, 189
Steroids and OKT3, 1055
Strand break rejoining, 599
Structure of radiation oncology, 235
Substrate depletion, 395
Surgery, 289, 429
Surgical clips, 579, 1009
Survival, 803, 809

T

Therapeutic gain, 1113
Thermal dosimetry, 635
Thermal radiosensitization, 133
Thermosensitivity, 623
Thermotolerance, 403
Thoracic irradiation, 459
3D patient setup, 873
3D treatment planning, 205
3D Visualization, 205
Three-dimensional conformal radiotherapy, 213
Three dimensional radiation therapy, 469
Three dimensional treatment planning, 1105
Thyroid dysfunction, 439
Thyroid function test, 439
Titanium interface dosimetry, 475
TLD, 1153
Tongue cancer, 333
Total androgen suppression, 911
Total-body irradiation, 71
Total body irradiation, 843
Toxicity, 843, 887
Transmission dosimetry, 931
Transrectal ultrasound, 775
Treatment plan-evaluation, 469
Treatment planning, 451, 691, 727, 917, 923, 1147
Treatment standards, 13
Treatment verification, 697
Tumor bed, 579
Tumor hypoxia, 93
Tumor regression, 389
Tumors, 357
Tumor size, 859

U

Uncertainty, 943

V

Virtual simulation, 205
v-myc, 103
Volume rendering, 205

W

Waiting lists, 243
Wedge angles, 1147
Whole-body hyperthermia, 1087
Whole body irradiation, 85

X

X-Ray therapy, 277

Z

Zoladex, 911